Discovering Factors in the Clinical Study Journey of Patients With OCD

NCT05881356 | Recruiting

• 1 other identifier: 91191727
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

This research aims to collect comprehensive data on the clinical trial experience of OCD patients. Its goal is to identify the factors that limit patients' ability to join or complete a trial successfully. Clinical trial participation often favors specific demographic groups, and limited research exists on the impact of trial attributes on participation. Therefore, this study aims to analyze data from various demographic groups and identify any recurring trends that could provide valuable insights for future OCD patients.

Conditions

OCD; Obsessive-Compulsive Disorder

Keywords

OCD; Obsessive-Compulsive Disorder

Outcome Measures

Primary Outcomes (2)

• Rate of participants who decide to enroll in a OCD clinical study.

  3 months

• Number of OCD patients who remain in clinical trial until completion.

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Participants with OCD who are actively considering involvement in an observational clinical trial, but have not yet completed enrollment and registration.

You may qualify if:

• Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.
• Participant has a diagnosis of OCD.
• Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.

You may not qualify if:

• Pregnant or lactating woman
• Enrolled in another research study
• Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Study Sites (1)

Power Life Sciences

San Francisco, California, 94107, United States

RECRUITING

Related Publications (3)

• Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment. JAMA. 2017 Apr 4;317(13):1358-1367. doi: 10.1001/jama.2017.2200.

  PMID: 28384832 BACKGROUND

• Albert U, Marazziti D, Di Salvo G, Solia F, Rosso G, Maina G. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy. Curr Med Chem. 2018;25(41):5647-5661. doi: 10.2174/0929867325666171222163645.

  PMID: 29278206 BACKGROUND

• Bidlack JM, Lockshin RA. Evolution of LDH isozymes during programmed cell death. Comp Biochem Physiol B. 1976;55(2):161-6. doi: 10.1016/0305-0491(76)90223-6. No abstract available.

  PMID: 963971 BACKGROUND

MeSH Terms

Conditions

Obsessive-Compulsive Disorder

Condition Hierarchy (Ancestors)

Anxiety Disorders; Mental Disorders

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

415-900-4227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 19, 2023
• First Posted: May 31, 2023
• Study Start: June 1, 2024
• Primary Completion: June 1, 2025
• Study Completion (Estimated): June 1, 2026
• Last Updated: May 31, 2023

Record last verified: 2023-05

Locations

US (1)